Avenue Therapeutics (ATXI) Competitors $0.25 -0.02 (-7.68%) As of 01:13 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. SHPH, REVB, SBFM, TCRT, NCNA, ENTO, CERO, EVAX, GNPX, and VCNXShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Shuttle Pharmaceuticals (SHPH), Revelation Biosciences (REVB), Sunshine Biopharma (SBFM), Alaunos Therapeutics (TCRT), NuCana (NCNA), Entero Therapeutics (ENTO), CERo Therapeutics (CERO), Evaxion Biotech A/S (EVAX), Genprex (GNPX), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Shuttle Pharmaceuticals Revelation Biosciences Sunshine Biopharma Alaunos Therapeutics NuCana Entero Therapeutics CERo Therapeutics Evaxion Biotech A/S Genprex Vaccinex Shuttle Pharmaceuticals (NASDAQ:SHPH) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the media refer more to SHPH or ATXI? In the previous week, Shuttle Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Shuttle Pharmaceuticals and 0 mentions for Avenue Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score. Company Overall Sentiment Shuttle Pharmaceuticals Neutral Avenue Therapeutics Neutral Do insiders and institutionals hold more shares of SHPH or ATXI? 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 39.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer SHPH or ATXI? Avenue Therapeutics received 147 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformShuttle PharmaceuticalsN/AN/AAvenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% Which has more volatility and risk, SHPH or ATXI? Shuttle Pharmaceuticals has a beta of -1.63, indicating that its stock price is 263% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Which has better valuation & earnings, SHPH or ATXI? Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShuttle PharmaceuticalsN/AN/A-$6.59M-$4.15-0.09Avenue TherapeuticsN/AN/A-$10.38M$18.350.01 Is SHPH or ATXI more profitable? Avenue Therapeutics' return on equity of -471.57% beat Shuttle Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Shuttle PharmaceuticalsN/A -583.02% -258.92% Avenue Therapeutics N/A -471.57%-296.50% SummaryAvenue Therapeutics beats Shuttle Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Remove Ads Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$514,000.00$6.44B$5.30B$7.16BDividend YieldN/A2.85%4.87%4.06%P/E Ratio0.016.8322.8717.50Price / SalesN/A190.01356.4785.03Price / CashN/A65.6738.1634.64Price / Book0.135.656.233.82Net Income-$10.38M$142.17M$3.20B$247.19M7 Day Performance-19.55%-11.22%-8.27%-7.19%1 Month Performance-74.98%-14.31%-3.22%-9.97%1 Year Performance-97.73%-18.16%3.38%-7.26% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.4879 of 5 stars$0.25-7.7%N/A-97.6%$514,000.00N/A0.014Gap DownSHPHShuttle Pharmaceuticals1.0357 of 5 stars$0.39flatN/AN/A$2.43MN/A-0.095Gap UpREVBRevelation Biosciences1.3658 of 5 stars$2.63-2.6%N/A-93.2%$2.38MN/A-0.0110SBFMSunshine Biopharma2.3773 of 5 stars$1.91-4.5%$15.00+685.3%-83.0%$2.34M$32.96M-0.013TCRTAlaunos Therapeutics1.071 of 5 stars$1.46flatN/A-76.8%$2.34M$7,000.000.0040Upcoming EarningsShort Interest ↓Gap UpNCNANuCana3.0075 of 5 stars$0.87-31.8%$25.00+2,764.3%-87.0%$2.31MN/A-0.0830Gap UpENTOEntero Therapeutics0.4886 of 5 stars$0.48-0.1%N/AN/A$2.28MN/A0.009CEROCERo TherapeuticsN/A$0.73-2.8%N/A-99.7%$2.21MN/A0.008Gap DownHigh Trading VolumeEVAXEvaxion Biotech A/S2.5351 of 5 stars$1.85+5.1%$20.00+981.1%-90.6%$2.17M$3.30M-1.2860Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGNPXGenprex4.2114 of 5 stars$0.25-9.5%$10.00+3,976.6%-86.1%$2.09MN/A0.0020Upcoming EarningsGap DownVCNXVaccinexN/A$0.76+1.5%N/A-92.2%$1.98M$388,000.00-0.0240Gap Up Remove Ads Related Companies and Tools Related Companies Shuttle Pharmaceuticals Alternatives Revelation Biosciences Alternatives Sunshine Biopharma Alternatives Alaunos Therapeutics Alternatives NuCana Alternatives Entero Therapeutics Alternatives CERo Therapeutics Alternatives Evaxion Biotech A/S Alternatives Genprex Alternatives Vaccinex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
